|
HCV | Abstract Library |
 |
|
The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors. |
Abstract Details |
 |
|
|
|
|
|
|
|
Pharmacokinetic Interactions Between the HCV Protease Inhibitor Boceprevir and Ritonavir-Boosted HIV-1 Protease Inhibitors Atazanavir, Darunavir, and Lopinavir |
|
|
|
|
|
Hulskotte EG, Feng HP, Xuan F, van Zutven MG, Treitel MA, Hughes EA, O'Mara E, Youngberg SP, Wagner JA, Butterton JR. Clin Infect Dis. 2012 Nov 15. [Epub ahead of print] |
|
|
|
|
|
Source
Merck Sharp & Dohme Corp., Oss, The Netherlands.
Abstract
Background. Boceprevir represents a new treatment option for hepatitis C (HCV)-infected patients, including those with HCV/human immunodeficiency virus (HIV) coinfection; however, little is known about pharmacokinetic interactions between boceprevir and antiretroviral drugs.Methods. A randomized, open-label study to assess the pharmacokinetic interactions between boceprevir and ritonavir-boosted protease inhibitors (PI/r) was conducted in 39 healthy adults. Subjects received boceprevir (800 mg, three times daily) for 6 days and then received PI/r as follows: atazanavir (ATV) 300 mg once daily, lopinavir (LPV) 400 mg twice daily, or darunavir (DRV) 600 mg twice daily, each with ritonavir (RTV) 100 mg on days 10-31, plus concomitant boceprevir on days 25-31.Results. Boceprevir decreased the exposure of all PI/r, with AUC(0-last) geometric mean ratios (GMR [90% confidence interval]) of 0.65 (0.55-0.78) for ATV/r; 0.66 (0.60-0.72) for LPV/r, and 0.56 (0.51-0.61) for DRV/r. Coadministration with boceprevir decreased RTV AUC(τ) by 22%-36%. ATV/r did not significantly affect boceprevir exposure, but boceprevir AUC(τ) was reduced by 45% and 32% when coadministered with LPV/r and DRV/r, respectively. Overall, treatments were well tolerated with no unexpected adverse events.Conclusions. Concomitant administration of boceprevir with PI/r resulted in reduced exposures of PI and boceprevir. These drug-drug interactions may reduce the effectiveness of PI/r and/or boceprevir when coadministered.
|
|
|
|
|
|
|
|
|
|
|
|
|
|